The Turkish guideline for the diagnosis and management of atopic dermatitis-2018

Basit Öğe Kaydı
dc.contributor.authorErtam, Ilgen
dc.contributor.authorSu, Ozlem
dc.contributor.authorAlper, Sibel
dc.contributor.authorSaricaoglu, Hayriye
dc.contributor.authorKaradag, Ayse Serap
dc.contributor.authorDemirsoy, Evren Odyakmaz
dc.contributor.authorBorlu, Murat
dc.date.accessioned2019-10-27T10:45:45Z
dc.date.available2019-10-27T10:45:45Z
dc.date.issued2018
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground and Design: Atopic dermatitis (AD) has a complicated etiopathogenesis and difficulties in diagnosis and treatment from time to time. Because of the disease which different approaches can be seen rationalize the need for an algorithm for the diagnosis, classification, etiopathogenesis, diagnostic tests and therapeutic approach. Therefore, authors from Dermatoallergy Working Group of the Turkish Society of Dermatology aimed to create an AD guideline for the diagnosis, treatment and followup. Materials and Methods: Each section of the guideline has been written by a different author. The prepared sections were evaluated in part by e-mail correspondence and have taken its final form after revision in the last meeting held by the participation of all authors. Results: The guideline includes the diagnosis, classification, etiopathogenesis, diagnostic tests and therapeutic approach of AD. Lesions show age-related morphology and distribution. There are no in vivo/in vitro tests that have high sensitivity and specificity that can be used to identify AD and trigger factors. The first step of treatment consists of moisturizers, topical corticosteroids and calcineurin inhibitors, respectively. Moisturizers are used therapeutically in all forms of AD. Topical corticosteroids are the first agents to be used when moisturizers are inadequate. Topical calcineurin inhibitors should be used in lesions resistant to corticosteroids, for proactive treatment, special areas. Antimicrobials agents and antiseptics should only be added to treatment when clinical signs of infection are present. And in topical treatment-resistant cases, second-line treatment is phototherapy or oral cyclosporine. The biologic agent, dupilumab, is promising in the treatment of severe AD. Conclusion: AD is a disease that can be challenging for the physician in terms of treatment and follow-up. Depending on evidence-based data (and individual experiences), this guideline will have a leading role in the diagnosis and treatment of AD and help the physician to overcome the challenges in the management.en_US
dc.identifier.doi10.4274/turkderm.87143
dc.identifier.endpage23en_US
dc.identifier.issn1019-214X
dc.identifier.issn1308-6294
dc.identifier.issn1019-214Xen_US
dc.identifier.issn1308-6294en_US
dc.identifier.issue1en_US
dc.identifier.startpage6en_US
dc.identifier.urihttps://doi.org/10.4274/turkderm.87143
dc.identifier.urihttps://hdl.handle.net/11454/31198
dc.identifier.volume52en_US
dc.identifier.wosWOS:000435797400003en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isotren_US
dc.publisherDeri Zuhrevi Hastaliklar Dernegien_US
dc.relation.ispartofTurkderm-Turkish Archives of Dermatology and Venerologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAtopic dermatitisen_US
dc.subjectalgorithmen_US
dc.subjectguidelineen_US
dc.subjectdiagnosisen_US
dc.subjecttreatmenten_US
dc.subjectTurkeyen_US
dc.titleThe Turkish guideline for the diagnosis and management of atopic dermatitis-2018en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu